Clear Harbor Asset Management LLC Acquires 3,006 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Clear Harbor Asset Management LLC increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 124.5% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 5,421 shares of the biopharmaceutical company’s stock after acquiring an additional 3,006 shares during the quarter. Clear Harbor Asset Management LLC’s holdings in Regeneron Pharmaceuticals were worth $3,862,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in REGN. AE Wealth Management LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 19.4% in the 2nd quarter. AE Wealth Management LLC now owns 547 shares of the biopharmaceutical company’s stock worth $575,000 after buying an additional 89 shares during the period. Pacer Advisors Inc. raised its stake in Regeneron Pharmaceuticals by 9.5% in the second quarter. Pacer Advisors Inc. now owns 16,464 shares of the biopharmaceutical company’s stock worth $17,304,000 after buying an additional 1,434 shares in the last quarter. Sei Investments Co. raised its position in shares of Regeneron Pharmaceuticals by 2.2% in the 2nd quarter. Sei Investments Co. now owns 24,944 shares of the biopharmaceutical company’s stock worth $26,214,000 after acquiring an additional 537 shares in the last quarter. Kayne Anderson Rudnick Investment Management LLC lifted its position in shares of Regeneron Pharmaceuticals by 28.7% during the second quarter. Kayne Anderson Rudnick Investment Management LLC now owns 5,657 shares of the biopharmaceutical company’s stock valued at $5,946,000 after buying an additional 1,263 shares during the last quarter. Finally, Frank Rimerman Advisors LLC boosted its position in shares of Regeneron Pharmaceuticals by 19,133.3% in the 2nd quarter. Frank Rimerman Advisors LLC now owns 577 shares of the biopharmaceutical company’s stock worth $606,000 after purchasing an additional 574 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 1.7 %

Shares of REGN opened at $681.58 on Tuesday. The firm’s fifty day moving average is $738.60 and its two-hundred day moving average is $948.80. The stock has a market cap of $74.90 billion, a PE ratio of 16.87, a price-to-earnings-growth ratio of 1.61 and a beta of 0.10. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 52-week low of $666.25 and a 52-week high of $1,211.20.

Analysts Set New Price Targets

A number of research firms have commented on REGN. Piper Sandler decreased their price target on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. UBS Group downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $1,130.00 to $738.00 in a research report on Thursday, January 16th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd. Sanford C. Bernstein dropped their price objective on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a report on Tuesday, January 7th. Finally, Wolfe Research initiated coverage on Regeneron Pharmaceuticals in a research report on Friday, November 15th. They set an “outperform” rating and a $1,150.00 price target for the company. One research analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $1,015.38.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.